Exposure to viral hepatitis has long been recognized as an occupational risk for healthcare personnel, with recommendations previously established for the management of occupational exposures to hepatitis C virus (HCV). This notice, which is based on current laboratory guidance, updates the 2001 HCV testing algorithm for healthcare personnel. Postexposure prophylaxis (PEP) of hepatitis C is not recommended, as outlined in the 2001 MMWR on management of healthcare personnel who have occupational exposure to blood and other body fluids.

Test the source for HCV RNA*. If the source is HCV RNA positive, or if HCV infection status unknown, follow the algorithm below. After a needlestick or sharps exposure to HCV-positive blood, the risk of HCV infection is approximately 1.8%². If the healthcare worker does become infected, follow AASLD/IDSA guidelines (www.hcvguidelines.org) for management and treatment of hepatitis C.

---

1If it is not possible to test source for HCV RNA, then test for antibodies to HCV (anti-HCV) and screen HCW exposed to anti-HCV positive source. Note that persons with acute infection may test HCV RNA positive but anti-HCV negative.

1In a nationally representative population sample with low (1%) HCV infection prevalence, 22% of anti-HCV positive results were determined to be false-positive. An additional 10% had indeterminate results in a confirmatory assay; most were likely to be false-positive. Among the subset of persons testing anti-HCV screening reactive and subsequently HCV RNA negative, 50% of the anti-HCV tests were false-positive.³

1Anti-HCV testing at >= 6 months with reflex to HCV RNA test, if positive, could also be done.

---

*Continued on next page*
A single negative HCV RNA test using currently available FDA-approved tests in the US (all with lower limit of detection <100 IU/mL in serum) is considered sufficient to rule out chronic HCV infection when screening an HCV antibody-positive individual with no known ongoing risk of exposure. HCV RNA becomes detectable within 3 weeks after exposure even when the antibody is still undetectable. Persons who develop symptoms of acute HCV infection such as jaundice may be tested earlier than 3 weeks, but if negative would require re-testing at ≥ 3 weeks. Spontaneous clearance of acute infection may occur up to six months after exposure, therefore persons testing HCV RNA positive < 6 months after exposure should be tested again at ≥ 6 months to determine infection status.

All patients with current HCV infection as evidenced by a positive HCV RNA test result should be evaluated by a practitioner with expertise in assessment of liver disease severity and HCV treatment. Guidance for hepatitis C treatment may be found at www.hcvguidelines.org and is changing rapidly with the advent of new therapies.

Spontaneous clearance of infection may occur up to six months after exposure; persons testing HCV RNA positive < 6 months after exposure should be tested again at ≥ 6 months after exposure to determine infection status.

References
